Corvus Pharmaceuticals

1. Soquelitinib AD Ph3 interimLate 2026Soquelitinib AD Ph3 interim, Late 2026, notable
2. Soquelitinib ALPS Ph3 interimLate 2026Soquelitinib ALPS Ph3 interim, Late 2026, notable
3. Soquelitinib PTCL Ph3 interimLate 2026Soquelitinib PTCL Ph3 interim, Late 2026, notable
4. Soquelitinib Atopic Dermatitis Ph2 topline1H 2027Soquelitinib Atopic Dermatitis Ph2 topline, 1H 2027, thesis-defining

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.